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ABSTRACT
Angiopoietins (Angs) are endothelium-selective ligands that ex-
ert most of their actions through the Tie-2 receptor. It is widely
accepted that Ang-1 promotes the structural integrity of blood
vessels and exhibits anti-inflammatory properties. In contrast,
the role of Ang-2 remains less clear because it has been shown
to behave as a Tie-2 agonist or antagonist under different
experimental conditions. To define the role of Ang-2 in acute
inflammation, we studied the effects of recombinant Ang-2
administration in vivo. We show herein that Ang-2, but not
Ang-1, induces edema formation in the mouse paw in a dose-
dependent manner; the edema seems to be fast-peaking (max-
imum at 30 min) and resolves within 4 h. The effect of Ang-2 is
blocked by the coadministration with a soluble form of the Tie-2
receptor or Ang-1. NO and prostaglandin E2 levels in mouse
paw following the injection of Ang-2 remained unaltered, sug-
gesting that the action of Ang-2 does not involve these medi-
ators. In addition, Ang-2 exerted a weak stimulatory effect on
leukocyte migration in the mouse paw. Similarly, Ang-2 injected
into the mouse air pouch produced only a modest effect on cell
extravasation that peaked at 30 min. However, when cell mi-
gration was elicited using zymosan, Ang-2 significantly inhib-
ited leukocyte migration. We conclude that Ang-2 by itself
stimulates the extravasation of cell-poor fluid, but in the pres-
ence of ongoing inflammation it reduces cellular infiltration in
tissues.
The acute inflammatory response is associated with an
increase in vascular permeability and cellular infiltration
(Nathan, 2002). Both the extravasation of fluid and proteins
and the accumulation of leukocytes at the inflammatory site
contribute to edema formation. Several mediators involved in
inflammation have been identified over the years. Hista-
mine, serotonin, bradykinin, and prostaglandins (PGs), to
name a few, trigger an increase in vascular permeability,
whereas cytokines promote the expression of molecules re-
sponsible for rolling, firm adhesion, and diapedesis of circu-
lating white blood cells (Malik and Lo, 1996; Nathan, 2002).
The list of inflammatory mediators also includes a number of
growth factors, such as vascular endothelial growth factor
(VEGF), that increase both vascular permeability and leuko-
cyte infiltration (Dvorak et al., 1995; Kim et al., 2001a).
Although VEGF was initially identified as a factor that
induces vascular permeability, it has been studied most in
the context of angiogenesis. VEGF is a receptor tyrosine
kinase ligand that stimulates endothelial cell (EC) prolifer-
ation and migration and promotes EC organization into ves-
sel structures (Ferrara et al., 2003; Zachary, 2003). Because
angiogenesis and inflammation are two tightly linked pro-
cesses, the search for factors that modify the inflammatory
response among angiogenic growth factors seemed natural.
The newly discovered growth factor angiopoietin-1 (Ang-1)
has been shown not only to promote vessel stabilization dur-
ing angiogenesis, but also to inhibit vascular permeability
and exert anti-inflammatory effects (Davis et al., 1996; Thur-
ston et al., 1999; Gamble et al., 2000). Ang-1 belongs to a
family of proteins that bind to the Tie-2 receptors on EC and
is a Tie-2 agonist (Davis et al., 1996). The second member of
the Ang family, Ang-2, can inhibit Ang-1-induced Tie-2 re-
ceptor phosphorylation on EC but stimulates phosphoryla-
tion of ectopically expressed Tie-2 receptor in transfected
fibroblasts (Maisonpierre et al., 1997). In addition, using
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high concentrations or prolonged incubation times with
Ang-2 led to the phosphorylation of Tie-2 receptors on some
types of EC (Kim et al., 2000; Teichert-Kuliszewska et al.,
2001); thus, Ang-2 is referred to as a context-dependent an-
tagonist. The least studied angiopoietin so far is Ang-4.
Ang-4 has been shown to evoke an agonist response upon
binding to the Tie-2 receptor, sharing many of the actions of
Ang-1 on cultured cells (Valenzuela et al., 1999; Lee et al.,
2004).
If Ang-2 truly acts as a Tie-2 antagonist on the endothe-
lium, one would expect this angiopoietin to promote vascular
permeability and aggravate inflammation; however, the ac-
tion of Ang-2 in these phenomena has not been examined to
date. Because of the conflicting results on the action of Ang-2
on Tie-2 receptor activation in vitro, valid conclusions regard-
ing the ability of Ang-2 to affect vascular leakage can only be
drawn using in vivo models. To this end, we used two in vivo
inflammatory mouse models of acute inflammation: the
mouse hind paw and air pouch. We have found that Ang-2
administered alone promotes vascular leakage that is char-
acterized by restricted migration of leukocytes, whereas it
acts as an inhibitor of zymosan-induced cell migration.
Materials and Methods
Mouse Paw Edema. All studies were performed in accordance
with European Union regulations for the handling and use of labo-
ratory animals and were approved by the local committee. Male
Swiss mice (CD-1; Charles River Italica, Calco, Italy) weighing 30 
2 g were divided into groups (n  8/group) and lightly anesthetized
with 4% enflurane mixed with 0.5 l/min O2 and 0.5 l/min N2O. Each
group of animals received subplantar administration of 50 l of
saline that contained either bovine serum albumin (0.1%, vehicle),
Ang-2 (30–300 ng), Ang-1 (300 ng), Ang-4 (300 ng), or VEGF (1–10
ng). In a separate set of experiments, a soluble form of the Tie-2
receptor (3000 ng; 1:10 ratio with Ang-2) was coadministered with
Ang-2 in the same final volume (50 l). To verify a possible interplay
between VEGF, Ang-1, and Ang-2, mice were injected with the com-
bination of VEGF plus Ang-1 or VEGF plus Ang-2. The volume was
measured using a hydroplethysmometer specially modified for small
volumes (Ugo Basile, Comerio, Italy) immediately before subplantar
injection and 0.5, 1, 2, 3, and 4 h thereafter. The same operator
always performed the double-blind assessment of paw volume. The
increase in paw volume was calculated by subtracting the initial paw
volume (basal) from the paw volume measured at each time point.
Mouse Air Pouch. To generate air pouches, mice were anesthe-
tized (ketamine/xylazine) on day 0 and received an injection of 5 ml
of sterile air into the back (n  6/group). Three days later, the
patency of the pouch formed was maintained by injecting 2.5 ml of
sterile air at the same site. On day 6, 1 ml of vehicle (bovine serum
albumin plus saline) or Ang-2 (300 ng) was injected into the air
pouch. Mice were sacrificed 0.5, 1, or 2 h following injection of either
Ang-2 or vehicle by cervical dislocation, and the exudates in the
pouch were collected by gently washing the pouch with 1 ml of sterile
saline. The liquid collected was centrifuged, and the pellet obtained
was resuspended in 500 l of saline. Leukocyte counts were per-
formed by diluting an aliquot of the cell suspension in Turk’s solution
using a microscope. The person scoring the samples was unaware of
the treatment.
In another set of experiments, mice that had the pouch formed as
described above were injected on day 6 with zymosan (1 ml of 1%
w/v). Ang-2 was administered in the pouch 30 min before injection of
zymosan. Four hours later, the animals were sacrificed, and the
leukocyte number was determined as described above.
Myeloperoxidase Measurement. Mice were killed with carbon
dioxide at 0.5, 1, or 2 h after Ang-2 administration, and the paws
were weighed, cut, and homogenized in 1 ml of hexadecyltrimethyl-
ammonium bromide buffer containing 5 g of hexadecyltrimethylam-
monium bromide in 1 l of potassium phosphate buffer (50 mM, pH
6.0) using a Polytron homogenizer (two cycles of 10 s at maximum
speed). After centrifugation at 10,000 rpm for 2 min, supernatant
fractions were assayed for myeloperoxidase (MPO) activity as an
estimate of the presence of neutrophils in the tissues. Briefly, sam-
ples (20 l) were mixed with phosphate buffer (180 l) containing 1
mM O-dianisidine dihydrochloride and 0.001% hydrogen peroxide in
a microtiter plate. Absorbance was measured at 450 nm, performing
three readings at 30-s intervals. The calculation of MPO units was
based on the fact that 1 U MPO equals 1 mol H2O2 generated per
min and that 1 mol H2O2 gives a change in absorbance of 1.13 
102 (change in absorbance  nanometers per minute).
NOx and PGE2 Exudate Levels. Mice from different groups
were killed with carbon dioxide 0.5, 1, or 2 h after Ang-2 adminis-
tration. Paws were cut and centrifuged at 4000 rpm for 30 min.
Exudates (supernatants) were collected with 100 l of saline and
used for NOx (nitrite plus nitrate) and PGE2 quantification. To
determine NOx levels, proteins were removed from the exudates with
30% ZnSO4. Supernatants and a standard curve of sodium nitrate
were incubated in a microplate with cadmium for 1 h to convert NO3

to NO2
. After centrifugation at 14,000 rpm for 15 min, total nitrite
(NOx) content was determined fluorometrically in microtiter plates
using a standard curve of sodium nitrite. NO concentration in the
samples was calculated using the internal standard curve. PGE2
levels were determined in deproteinized exudates by radioimmuno-
assay.
Drugs and Reagents. Bradford reagent was obtained from Bio-
Rad (Segrate, Italy). [3H]PGE2 was obtained from PerkinElmer Life
and Analytical Sciences (Boston, MA). Recombinant human angio-
poietins, VEGF1–165, and soluble Tie-2 were purchased from R&D
Systems (Minneapolis, MN). The purity for each of the recombinant
growth factors or proteins used was as follows: Ang-1, 90%; Ang-2,
97%; Ang-4, 85%; VEGF1–165, 97%; and soluble Tie-2, 90%, as
determined by SDS- polyacrylamide gel electrophoresis and visual-
ized by silver staining. Professor Ciabattoni (University of Chieti,
Chieti, Italy) provided the antibody against PGE2. All the other
reagents and compounds used were obtained from Sigma-Aldrich
(St. Louis, MO).
Statistical Analysis.Data were expressed as mean S.E.M. The
level of statistical significance was determined by one-way analysis
of variance, followed by Bonferroni post test for multiple compari-
sons using Prism software (GraphPad Software Inc., San Diego, CA).
Results
Ang-2 Induces Edema Formation in Vivo. Given that
Ang-2 blocks phosphorylation of Tie-2 by Ang-1 on vascular
EC, exerting a destabilizing effect, and that transgenic over-
expression of Ang-2 in vivo results in discontinuous and
leaky vessels (Maisonpierre et al., 1997), we postulated that
acute administration of recombinant Ang-2 protein in vivo
could alter endothelial integrity and increase vascular leak-
age. To determine the ability of Ang-2 to stimulate edema
formation, we assessed changes in paw volume after subplan-
tar injection of Ang-2. Ang-2 administration in the hind paw
of CD1 Swiss mice resulted in a dose- and time-dependent
increase in paw volume that was fast in onset, peaking at 30
min and lasting at least 3 h (Fig. 1A). To determine whether
Tie-2 agonists have a similar effect to that observed with
Ang-2 on edema formation, we used 300 ng/paw (equivalent
to the maximal dose of Ang-2 used) of Ang-1 or Ang-4. Unlike
Ang-2, Ang-1 did not trigger edema formation in the hind
paw, whereas Ang-4 caused an inflammatory response that
peaked at 1 h (Fig. 1B).
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Soluble Tie-2 and Ang-1 Inhibit Ang-2-Induced
Edema. Angiopoietins bind a common receptor on the EC
surface, the Tie-2 receptor (Yancopoulos et al., 2000). To
verify that the effects of Ang-2 were specific, we repeated the
Ang-2 injections mixed with 10-fold excess of a soluble form
of Tie-2 (Tie-2/Fc; 3000 ng). Whereas Tie-2/Fc alone did not
have any effect, coinjection with Ang-2 abrogated changes in
paw volume stimulated by the latter (Fig. 2A). To determine
the ability of Ang-1 to protect against Ang-2-induced vascu-
lar leakage, mice were coinjected with an Ang-1/Ang-2 mix-
ture at a 1:1 ratio. Under these conditions, Ang-1 abolished
Ang-2-stimulated edema (Fig. 2B).
Ang-2-Induced Edema Is Independent of NO and
PGE2 Generation and Characterized by Only Minor
Cellular Infiltration. To determine the mechanisms that
mediate Ang-2 edema, we measured NO and PGE2 (common
mediators produced by EC that alter EC permeability) in
vehicle- and Ang-2-treated tissues (Fig. 3, A and B). After
subplantar injections of the dose of Ang-2 that caused max-
imal edema, no significant increase in both mediators was
noted after 0.5, 1, or 2 h. To investigate whether the edema
consisted mainly of fluid or was also leukocyte-rich, we mea-
sured tissue MPO activity, an enzyme found in high amounts
in phagocytes. Treatment of mice with Ang-2 resulted in only
a small increase in MPO activity in the paw that was signif-
icant 2 h postinjection (Fig. 3C). Histological sections from
animals at several different time points after Ang-2 treat-
ment confirmed that the edema observed in response to
Ang-2 consisted mainly of fluid with only very few infiltrat-
ing cells (unpublished data).
To better evaluate the effect of Ang-2 on cellular infiltra-
tion, we switched to a model that allows quantitation of the
number of cells migrated, the air pouch model. The injection
of Ang-2 alone into the pouch triggered the migration of a few
cells (mainly neutrophils), which was similar to what was
observed in the hind paw. However, when Ang-2 was given in
the presence of ongoing inflammation, it reduced the number
of infiltrating cells in response to zymosan by approximately
50% (Fig. 4). In the same model, Ang-1 had no effect on cell
migration.
Effect of Angiopoietins on VEGF-Induced Increase
in Paw Volume. VEGF is a well-documented permeability-
inducing growth factor (Dvorak et al., 1995). Because of its
interaction with the angiopoietins during angiogenesis, we
sought to determine whether angiopoietins modify VEGF-
induced vascular permeability. VEGF produced a time- and
dose-dependent increase in paw volume (Fig. 5A), which ex-
hibited similar kinetics with Ang-2, reaching a maximum
0.5 h after the injection and receding after 4 h. We proceeded
to investigate whether the coinjection of these two factors
would have an additive effect. Administration of a submaxi-
mal Ang-2 dose (30 ng) along with a submaximal VEGF dose
(3 ng) resulted in additive edema formation after 0.5 h (Fig.
5B). In contrast, coadministration of maximal Ang-2 and
VEGF doses resulted in an increase in paw volume that was
not greater than the increase observed when either growth
factor was used alone (Fig. 5C). When Ang-1 was used in
combination with VEGF, it prolonged the duration of edema
Fig. 1. Ang-2, but not Ang-1, promotes edema formation. A, CD1 mice
injected subplantarly with Ang-2 (30–300 ng/paw), and edema formation
measured at the indicated times. B, angiopoietins administered at 300
ng/paw, and edema measured up to 4 h. Values are mean  S.E.M.; n 
8 mice; , p  0.05; , p  0.01; and , p  0.001 versus vehicle.
Fig. 2. Soluble Tie-2 and Ang-1 prevent Ang-2-stimulated edema. A,
Ang-2 (300 ng) administered either alone or in combination with 10-fold
excess of soluble Tie-2 (Tie-2/Fc; 3000 ng). Values are mean S.E.M.; n
8 animals. , p  0.05; , p  0.01; and , p  0.001 versus vehicle; #,
p  0.05 and ##, p  0.01 versus Ang-2. B, Ang-2 or Ang-1 (300 ng each)
administered alone or in combination, and edema formation measured at
the indicated time. Values are mean  S.E.M.; n  8 mice. , p  0.01
and , p  0.001 versus vehicle; ##, p  0.01 versus Ang-2.
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without affecting the maximal response obtained in the pres-
ence of VEGF (Fig. 5D).
Discussion
The angiopoietin family of proteins includes four different
angiopoietins termed Ang-1 through Ang-4 (Yancopoulos et
al., 2000). Ang-1 is vital for neovascularization during devel-
opment because Ang-1-deficient mice exhibit embryonic le-
thality (Suri et al., 1996). Ang-1 lacks growth-stimulating
properties but promotes EC sprouting, migration, and sur-
vival (Koblizek et al., 1998; Witzenbichler et al., 1998; Papa-
petropoulos et al., 2000). Ang-4 shares many of the properties
of Ang-1 and, together with Ang-1, is classified as an agonist
of the Tie-2 receptor based on its ability to promote Tie-2
autophosphorylation (Valenzuela et al., 1999; Lee et al.,
2004). On the other hand, Ang-2 exhibits context-dependent
behavior because it can inhibit or stimulate Tie-2 receptor
phosphorylation under different conditions (Maisonpierre et
al., 1997; Kim et al., 2000; Papapetropoulos et al., 2000). This
is also reflected in the biological responses brought about by
Ang-2; for example, Ang-2 has been shown to both promote
EC migration (Mochizuki et al., 2002) and inhibit Ang-1-
stimulated EC migration (Witzenbichler et al., 1998). More
recently, based on observations of the ability of Ang-1 to
rescue the phenotype of Ang-2 knockouts, Gale et al. (2002)
suggested that Ang-2 in vivo acts a Tie-2 antagonist on vas-
cular EC, whereas it acts as a Tie-2 agonist on lymphatic
vessels. The varying behavior of Ang-2 in the different exper-
imental systems in vitro and its differential effects on vascu-
lar versus lymphatic endothelium make it difficult to predict
the actions of this growth factor in vivo on vascular leakage.
To determine the role of Ang-2 in vascular leakage, we used
recombinant Ang-2 and measured edema formation in the
mouse hind paw. Unlike what had been reported for Ang-2 in
vitro, where it has no effect on vascular permeability (Wang
et al., 2004), we observed that Ang-2 promoted edema forma-
tion in a time- and dose-dependent manner. Edema forma-
tion in response to Ang-2 was prevented by neutralizing its
action using a soluble form of the Tie-2 receptor. It should be
mentioned that targeted disruption of the Ang-2 locus results
in ascites formation and lethality soon after birth in mice
(Gale et al., 2002). This observation is not in conflict with the
present data because the increased leakage in Ang-2 knock-
out mice is caused by defects in lymphatic patterning during
development.
One of the cardinal features of inflammation is the leuko-
Fig. 3. MPO, NOx, and PGE2 production after Ang-2 administration.
Mouse paws were injected with vehicle or Ang-2 (300 ng); Nox levels (A),
PGE2 levels (B), and MPO activity (C) were measured in the exudates
after 0.5, 1, or 2 h. Values are mean  S.E.M.; n  6 mice. , p  0.01
versus vehicle.
Fig. 4. Effects of Ang-2 on leukocyte migration in the air pouch model. A,
Ang-2 (300 ng), Ang-1 (300 ng), or soluble Tie-2 (3000 ng) administered
into the air pouch, and leukocyte migration evaluated after 30 min. B,
Ang-2, Ang-1, or Tie-2 administered locally in the pouch 0.5 h before
zymosan administration. Values are mean  S.E.M.; n  6 animals. ,
p  0.01 and , p  0.001 versus vehicle.
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cyte migration into tissues. To determine whether Ang-2
stimulates transmigration of circulating leukocytes in addi-
tion to promoting fluid passage, we measured tissue MPO
activity and cell number after exposure to Ang-2 in the mouse
paw and air pouch model, respectively. We observed that
Ang-2 promoted a small but significant increase in neutro-
phil accumulation in tissues. Ang-2 could promote neutrophil
margination by acting either on the endothelium or on the
leukocytes themselves. A recent report by Lemieux et al.
(2005) showed that Ang-2 promotes a rapid translocation of
P-selectin on the EC surface and stimulates neutrophil ad-
herence to the endothelium. In the same report, neutrophils
were also shown to express functional Tie-2 receptors. Tie-2
activation by Ang-1 or Ang-2 stimulates platelet-activating
factor synthesis, whereas treatment with a combination of
Ang-1 and Ang-2 also triggers the functional up-regulation of
the 2-integrin complex to facilitate binding of polymorpho-
nuclear leukocytes to EC. Interestingly, in the present study,
Ang-2 blocked zymosan-induced leukocyte infiltration in the
air pouch, indicating that in the presence of this inflamma-
tory stimulus Ang-2 reduces excessive leukocyte mobiliza-
tion. Collectively, our data indicate that Ang-2 is efficient
in promoting vascular leakage when used by itself and has
a small effect on leukocyte trafficking; however, in the
presence of ongoing inflammation, it inhibits leukocyte
migration.
Although some observations have suggested that NO re-
duces permeability, recent in vivo observations and in vitro
studies using microvascular EC are consistent with a per-
meability-promoting effect of NO (Yuan, 2002). We have
confirmed in the mouse paw that NO derived from the endo-
thelium is critical for vascular leakage during acute
inflammation using endothelial NO synthase knockout mice
(Bucci et al., 2005). A link between Tie-2 receptor activation
and NO has also been proposed: NO was reported to be
increased following Ang-1 exposure and to contribute to the
angiogenic actions of Ang-1 (Babaei et al., 2003; Chen et al.,
2004). However, it should also be mentioned that we have
been unable to detect NO release from cultured human um-
bilical vein EC, as measured by its surrogate marker cGMP
(Papapetropoulos et al., 1999). In the present study, no
change in NOx in response to Ang-2 administration was
noted, suggesting that vascular leakage in response to Ang-2
does not result from increased NO production. To further
investigate the mechanism through which Ang-2 promotes
vascular leakage, we measured the levels of PGE2 in tissue
homogenates of vehicle- and Ang-2-treated mice. The data
obtained ruled out the possibility that this autacoid mediates
the action of Ang-2.
The working hypothesis in the field of angiogenesis is
currently that neovessel formation requires the temporal and
spatial integration of signals originating from both the Tie-2
Fig. 5. Interaction of VEGF and angiopoietins in edema formation. A, VEGF (1–10 ng/paw) administered subplantarly, and edema formation
measured at the indicated times. Values are mean S.E.M.; n 6 animals. , p 0.05; , p 0.01; and , p 0.001 versus vehicle. B, mice injected
subplantarly with Ang-2 (30 ng) alone, VEGF (3 ng) alone, or a combination of Ang-2 (30 ng) and VEGF (3 ng) before evaluation of edema formation.
Values are mean  S.E.M.; n  8 animals/group. , p  0.05 versus Ang-2; #, p  0.05; and ###, p  0.001 versus VEGF. C, mice injected subplantarly
with Ang-2 (300 ng) alone, VEGF (10 ng) alone, or a combination of Ang-2 (300 ng) and VEGF (10 ng), and edema formation determined. , p  0.01
and , p  0.001 versus Ang-2; #, p  0.05 versus VEGF. D, Ang-1 (300 ng) or VEGF (1 ng) injected alone or in combination, and edema formation
measured at the indicated times. , p  0.05; , p  0.01; and , p  0.001 versus Ang-1; ##, p  0.001 versus VEGF.
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and VEGF receptors. When the need for new blood vessels
arises, Ang-2 expression is up-regulated, blocking the vessel-
stabilizing action of Ang-1; this allows loosening of existent
vascular structures, which in turn enables VEGF (and other
growth factors) to promote EC migration, proliferation, and
organization of EC into networks (Gale and Yancopoulos,
1999). Once the new vessels have been formed, a concomitant
increase in Ang-1 levels and a decrease in Ang-2 levels are
observed, securing the structure of the newly formed vascu-
lature (Gale and Yancopoulos, 1999; Holash et al., 1999).
Because of the importance of the interaction of VEGF and the
angiopoietins in angiogenesis, we tested the effect of Ang-2
on the VEGF-induced increase in vascular permeability.
Similar to what has been shown in other vascular beds and
species, VEGF administration promoted dose-dependent
edema formation in the mouse paw. This edema had similar
kinetics and was of a comparable magnitude to the one ob-
served with Ang-2. When submaximal doses of both Ang-2
and VEGF were used, there was an additive effect of the two
growth factors after 0.5 h, whereas when maximal Ang-2 and
VEGF doses were used, no additivity was observed, suggest-
ing that Ang-2 and VEGF could be acting through similar
pathways. A recent review reported 46 different signaling
pathways that can be activated by VEGF in cultured EC
(Zachary and Gliki, 2001). However, only phospholipase C
and mitogen-activated protein kinase cascades have been
shown to mediate the increase in vascular permeability stim-
ulated by VEGF in microvessel preparations (Bates and
Harper, 2002). We observed that Ang-2 stimulated extracel-
lular signal-regulated kinase 1/2 phosphorylation (unpub-
lished data); experiments are underway to determine
whether the mitogen-activated protein kinase pathway me-
diates the increase in permeability brought about by Ang-2.
Ang-1, in addition to being important for angiogenesis, also
possesses anti-inflammatory properties. Genetic overexpres-
sion or overexpression following infection with adenovirus
carrying the Ang-1 gene protects the vasculature from
VEGF- and irritant-induced leakage (Thurston et al., 1999,
2000). Ang-1 also blocks the increase in permeability brought
about by a variety of agents (Gamble et al., 2000; Pizurki et
al., 2003), inhibits endothelial interleukin 8 production (Pi-
zurki et al., 2003), blocks VEGF-induced expression of adhe-
sion molecules, and reduces leukocyte adhesion and transmi-
gration in vitro (Gamble et al., 2000; Kim et al., 2001b;
Pizurki et al., 2003). The inhibition of VEGF-induced perme-
ability afforded by Ang-1 in vitro has been attributed to a
reduction in protein kinase C (PKC) activation, inhibition
of dissociation of -catenin from vascular endothelial cad-
herin, and stabilization of EC junctional complexes (Gamble
et al., 2000; Li et al., 2004; Wang et al., 2004). A different
PKC isoform (PKC) has been implicated in the inhibitory
action of Ang-1 on thrombin-induced permeability (Li et al.,
2004). Contrary to what we expected, administration of re-
combinant Ang-1 did not inhibit VEGF-induced vascular per-
meability but instead delayed edema resolution. The discrep-
ancy between in vivo and in vitro results can be easily
explained by the presence of additional types of cells that also
express angiopoietin receptors and contribute/modify the
Ang-1 response. The prolonged action of VEGF on permeabil-
ity in the presence of Ang-1 could result from the activation
of the neutrophil Tie-2 receptor, leading to increased adher-
ence of neutrophils to the endothelium and platelet-activat-
ing factor release (Lemieux et al., 2005). On the other hand,
the low levels of locally injected Ang-1 compared with the
levels achieved after overexpression, as well as the fact that
different vascular beds were studied, could account for the
differences between the present report and earlier in vivo
studies. In any case, our observations suggest that Ang-1 is
not a universal inhibitor of EC permeability as previously
thought.
In conclusion, we have shown that Ang-2 can act as a
modulator of the inflammatory response by promoting vas-
cular leakage. However, it does not exhibit the full features of
a classic inflammatory substance because it mainly stimu-
lates fluid passage without strongly promoting leukocyte mi-
gration. This effect of Ang-2 on endothelial barrier function
could be relevant for phenomena related to angiogenesis and
inflammation.
References
Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ, and Stewart DJ
(2003) Angiogenic actions of angiopoietin-1 require endothelium-derived nitric
oxide. Am J Pathol 162:1927–1936.
Bates DO and Harper SJ (2002) Regulation of vascular permeability by vascular
endothelial growth factors. Vascul Pharmacol 39:225–237.
Bucci M, Roviezzo F, Posadas I, Yu J, Parente L, Sessa WC, Ignarro LJ, and Cirino
G (2005) Endothelial nitric oxide synthase activation is critical for vascular leak-
age during acute inflammation in vivo. Proc Natl Acad Sci USA 102:904–908.
Chen JX, Lawrence ML, Cunningham G, Christman BW, and Meyrick B (2004)
HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery
endothelium. J Appl Physiol 96:612–620.
Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J,
Radziejewski C, Maisonpierre PC, et al. (1996) Isolation of angiopoietin-1, a ligand
for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161–1169.
Dvorak HF, Brown LF, Detmar M, and Dvorak AM (1995) Vascular permeability
factor/vascular endothelial growth factor, microvascular hyperpermeability and
angiogenesis. Am J Pathol 146:1029–1039.
Ferrara N, Gerber H-P, and LeCouter J (2003) The biology of VEGF and its recep-
tors. Nat Med 9:669–676.
Gale N, Thurston G, Hackett S, Renard R, Wang Q, McClain J, Martin C, Witte C,
Witte M, Jackson D, et al. (2002) Angiopoietin-2 is required for postnatal angio-
genesis and lymphatic patterning and only the latter role is rescued by angiopoi-
etin-1. Dev Cell 3:411–423.
Gale NW and Yancopoulos GD (1999) Growth factors acting via endothelial cell-
specific receptor tyrosine kinases: VEGFs, angiopoietins and ephrins in vascular
development. Genes Dev 13:1055–1066.
Gamble J, Drew J, Tresize L, Underwood A, Parsons M, Kasminkas L, Rudge J,
Yancopoulos G, and Vadas M (2000) Angiopoietin-1 is an anti-permeability and
anti-inflammatory agent in vitro and targets cells junctions. Circ Res 87:603–607.
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yan-
copoulos GD, and Wiegand SJ (1999) Vessel cooption, regression and growth in
tumors mediated by angiopoietins and VEGF. Science (Wash DC) 284:1994–1998.
Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, and Koh GY (2000) Angiopoietin-2 at
high concentration can enhance endothelial cell survival through the phosphati-
dylinositol 3-kinase/Akt signal transduction pathway. Oncogene 19:4549–4552.
Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, and Koh GY (2001a) Vascular endothe-
lial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vas-
cular cell adhesion molecule 1 (VCAM-1) and E-selectin through nuclear factor-
kappa B activation in endothelial cells. J Biol Chem 276:7614–7620.
Kim I, Moon SO, Park SK, Chae SW, and Koh GY (2001b) Angiopoietin-1 reduces
VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1,
VCAM-1 and E-selectin expression. Circ Res 89:477–479.
Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, and Risau W (1998) Angiopoi-
etin-1 induces sprouting angiogenesis in vitro. Curr Biol 8:529–532.
Lee HI, Cho C-H, Hwang S-J, Choi H-H, Kim K-T, Ahn SY, Kim J-H, Oh J-L, Lee
GM, and Koh GY (2004) Biological characterization of angiopoietin-3 and angio-
poietin-4. FASEB J 18:1200–1208.
Lemieux C, Maliba R, Favier J, Theoret J-F, Merhi Y, and Sirois MG (2005) Angio-
poietins can directly activate endothelial cells and neutrophils to promote proin-
flammatory responses. Blood 105:1523–1530.
Li X, Hahn CN, Parsons M, Drew J, Vadas MA, and Gamble JR (2004) Role of protein
kinase Czeta in thrombin-induced endothelial permeability changes: inhibition by
angiopoietin-1. Blood 104:1716–1724.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C,
Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. (1997) Angiopoietin-2,
a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (Wash
DC) 277:55–60.
Malik A and Lo S (1996) Vascular endothelial adhesion molecules and tissue inflam-
mation. Pharmacol Rev 48:213–229.
Mochizuki Y, Nakamura T, Kanetake H, and Kanda S (2002) Angiopoietin 2 stim-
ulates migration and tube-like structure formation of murine brain capillary
endothelial cells through c-Fes and c-Fyn. J Cell Sci 115:175–183.
Nathan C (2002) Points of control in inflammation. Nature (Lond) 420:846–852.
Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor DS, Li F, Altieri DC,
Ang-2 Promotes Vascular Leakage 743
 at A
SPET Journals on February 19, 2018
jpet.aspetjournals.org
D
ow
nloaded from
 
and Sessa WC (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the
Akt/survivin pathway. J Biol Chem 275:9102–9405.
Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos
GD, and Sessa WC (1999) Direct actions of angiopoietin-1 on human endothelium:
evidence for network stabilization, cell survival and interaction with other angio-
genic growth factors. Lab Investig 79:213–223.
Pizurki L, Zhou Z, Glynos K, Roussos C, and Papapetropoulos A (2003) Angiopoi-
etin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 produc-
tion. Br J Pharmacol 139:329–336.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, and
Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2
receptor, during embryonic angiogenesis. Cell 87:1171–1180.
Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Ben-
deck MP, Alitalo K, Dumont DJ, Yancopoulos GD, and Stewart DJ (2001) Biolog-
ical action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated
with activation of Tie2. Cardiovasc Res 49:659–670.
Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J,
McDonald DM, and Yancopoulos GD (2000) Angiopoietin-1 protects the adult
vasculature against plasma leakage. Nat Med 6:460–463.
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, and McDonald
DM (1999) Leakage-resistant blood vessels in mice transgenically overexpressing
angiopoietin-1. Science (Wash DC) 286:2511–2514.
Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J,
Copeland NG, Gilbert DJ, Jenkins NA, et al. (1999) Angiopoietins 3 and 4:
diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96:
1904–1909.
Wang Y, Pampou S, Fujikawa K, and Varticovski L (2004) Opposing effect of
angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions
requires activation of PKC beta. J Cell Physiol 198:53–61.
Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, and Isner JM (1998)
Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-
specific receptor tyrosine kinase Tie2. J Biol Chem 273:18514–18521.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, and Holash J (2000)
Vascular-specific growth factors and blood vessel formation. Nature (Lond) 407:
242–248.
Yuan SY (2002) Protein kinase signaling in the modulation of microvascular perme-
ability. Vascul Pharmacol 39:213–223.
Zachary I (2003) VEGF signalling: integration and multi-tasking in endothelial cell
biology. Biochem Soc Trans 31:1171–1177.
Zachary I and Gliki G (2001) Signaling transduction mechanisms mediating biolog-
ical actions of the vascular endothelial growth factor family. Cardiovasc Res
49:568–581.
Address correspondence to: Dr. Andreas Papapetropoulos, Laboratory of
Molecular Pharmacology, Department of Pharmacy, University of Patras,
Patras, Greece 26504. E-mail: apapapet@upatras.gr
744 Roviezzo et al.
 at A
SPET Journals on February 19, 2018
jpet.aspetjournals.org
D
ow
nloaded from
 
